Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clgc.2018.09.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lactobacillus reuteri Assists Engineered Bacteria That Target Tumors to Release PD-L1nb to Mitigate the Adverse Effects of Breast Cancer Immunotherapy.
Biotechnol J
December 2024
School of Pharmacy, Binzhou Medical University, Yantai, China.
Programmed death protein-ligand 1 (PD-L1) inhibitors demonstrate significant antitumor efficacy by modulating T-cell activity and inhibiting the PD-1/PD-L1 pathway, thus enhancing immune responses. Despite their robust effects, systemic administration of these inhibitors is linked to severe immune toxicity. To address this issue, we engineered a strain, REP, which releases PD-L1 nanoantibodies (PD-L1nb) to treat breast cancer and attenuate immunotherapy-related side effects.
View Article and Find Full Text PDFκ-carrageenan - Gelatin hydrogel embedding carvacrol loaded gold nanobipyramids for treating prostate cancer via fractionated photothermal-chemotherapy.
Int J Biol Macromol
December 2024
Marine Integrated Biomedical Technology Center, The National Key Research Institutes in Universities, Pukyong National University, Busan, Republic of Korea; Industry 4.0 Convergence Bionics Engineering, Pukyong National University, Busan, Republic of Korea; Major of Biomedical Engineering, Division of Smart Healthcare, College of Information, Pukyong National University, Busan, Republic of Korea. Electronic address:
Conventional treatment of prostate cancer need more specificity, and higher efficiency. The present work is the first attempt to utilize hydrogel-loaded carvacrol-based chemotherapy with fractionated photothermal therapy (F-PTT) using a 635 nm laser for its treatment. Gold nanobipyramids (AuNBPs) were used as drug carrier and photosensitizer.
View Article and Find Full Text PDFSuccessful treatment of tumor lysis syndrome associated with hepatic artery infusion chemotherapy in a patient with hepatocellular carcinoma: a case report.
J Med Case Rep
December 2024
Liver Cancer Institute, National Clinical Research Center for Interventional Medicine, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai, 200032, People's Republic of China.
Background: Tumor lysis syndrome is a life-threatening complication in the treatment of cancer. However, it rarely occurs in solid tumors, especially in hepatocellular carcinoma.
Case Presentation: We present a 52-year-old male Asian patient with advanced hepatocellular carcinoma treated with hepatic artery infusion chemotherapy that resulted in tumor lysis syndrome.
Bacterial ghosts: A breakthrough approach to cancer vaccination.
Biomed Pharmacother
December 2024
Menzies Health Institute Queensland and School of Medical Science, Griffith University, Gold Coast Campus, Parklands Drive, Southport, QLD 4215, Australia.
Cancer is a devastating disease worldwide with high mortality rates and is a foremost concern for society. Immunotherapy has emerged as a promising strategy for treating cancer, harnessing the power of immune system to recognize and kill tumor cells. Bacterial ghosts (BGs), a novel platform in cancer vaccination, are suitable for personalized and effective immunotherapeutic interventions.
View Article and Find Full Text PDFMeningitis due to Gemella sp. in a patient with severe ENT conditions: case report and review of the literature.
Ann Clin Microbiol Antimicrob
December 2024
Laboratoire de Microbiologie, Centre Hospitalier de Valenciennes, Valenciennes, F-59300, France.
In June 2022, a 73-year-old man with a history of laryngeal and esophageal carcinoma was admitted to the emergency unit with sudden fever, confusion, and general condition deterioration. Initial assessments showed a fever of 38.5 °C, elevated C-reactive protein (CRP) at 209 mg/L, and a neutrophil count of 10.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!